Blane Mire, MD
Internal Medicine · Natchez, MSNPI 1326082397
Payments from drug & device makers
Across 525 payments — averaging $16.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$992
- Johnson & Johnson$744
- Boehringer Ingelheim$698
- Lilly USA, LLC$690
- AbbVie$683
- Merck$555
- plus $4K from 27 others
What the payments were for
- Food & beverage$8,30699%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 64 | $992 |
| Johnson & Johnson | 48 | $744 |
| Boehringer Ingelheim | 40 | $698 |
| Lilly USA, LLC | 44 | $690 |
| AbbVie(2 entities) | 44 | $683 |
| Merck | 39 | $555 |
| Amgen | 31 | $542 |
| Novo Nordisk | 30 | $513 |
| Astellas Pharma US Inc | 28 | $508 |
| AstraZeneca | 31 | $482 |
| Novartis | 28 | $410 |
| Sanofi-aventis U.S. LLC | 24 | $405 |
| GSK | 26 | $379 |
| Teva Pharmaceuticals USA, Inc. | 7 | $128 |
| Avanir Pharmaceuticals, Inc. | 8 | $104 |
| Abbott | 5 | $101 |
| Sanofi Pasteur Inc. | 3 | $58 |
| Amarin Pharma, Inc. | 3 | $55 |
| Edwards Lifesciences | 1 | $45 |
| Dexcom, Inc. | 3 | $44 |
| Biogen | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Biocryst US Sales Co., LLC | 1 | $20 |
| CSL Behring | 1 | $18 |
| Abiomed | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
| Medtronic | 1 | $13 |
| Braintree Laboratories, Inc. | 1 | $13 |
How this compares
$8,406 in reported general payments places this provider in the 90th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $105,296 |
| MounjaroTirzepatide | 85 | $91,595 |
| JardianceEmpagliflozin | 55 | $48,240 |
| TrulicityDulaglutide | 18 | $18,749 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $18,315 |
| JanuviaSitagliptin Phosphate | 27 | $17,214 |
| XareltoRivaroxaban | 17 | $16,226 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $15,319 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $14,021 |
| EliquisApixaban | 24 | $13,767 |
| FarxigaDapagliflozin Propanediol | 17 | $12,028 |
| NamzaricMemantine Hcl/Donepezil Hcl | 14 | $7,465 |
| Valsartan | 176 | $5,255 |
| Rosuvastatin Calcium | 317 | $4,202 |
| Atorvastatin Calcium | 401 | $2,414 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $690 | $110,345103 claims |
| Novo NordiskOzempic | $513 | $105,29675 claims |
| Boehringer IngelheimJardiance | $698 | $48,24055 claims |
| MerckJanuvia | $555 | $17,21427 claims |
| Johnson & JohnsonXarelto | $744 | $16,22617 claims |
| GSKTrelegy Ellipta | $379 | $15,31914 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $405 | $14,02116 claims |
| PfizerEliquis | $992 | $13,76724 claims |
| AstraZenecaFarxiga | $482 | $12,02817 claims |
| AbbVieNamzaric | $683 | $7,46514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Natchez
- Edward DalyNatchez$11K
- Kenneth StubbsNatchez$8K
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
- Kelly WilkinsonJackson$183K
- Magdy Gorgi-MikhailBiloxi$157K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.